Andy Chen
Stock Analyst at Wolfe Research
(3.53)
# 900
Out of 5,109 analysts
40
Total ratings
54.17%
Success rate
29.41%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Downgrades: Peer Perform | n/a | $849.95 | - | 3 | Nov 24, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Peer Perform | n/a | $9.59 | - | 3 | Nov 12, 2025 | |
| APLS Apellis Pharmaceuticals | Initiates: Peer Perform | n/a | $25.16 | - | 1 | Nov 6, 2025 | |
| ALNY Alnylam Pharmaceuticals | Upgrades: Peer Perform | n/a | $400.69 | - | 3 | Aug 4, 2025 | |
| VERA Vera Therapeutics | Downgrades: Peer Perform | n/a | $55.67 | - | 2 | Aug 4, 2025 | |
| BBIO BridgeBio Pharma | Initiates: Outperform | $49 | $76.53 | -35.97% | 1 | Jun 17, 2025 | |
| SRPT Sarepta Therapeutics | Initiates: Peer Perform | n/a | $22.32 | - | 1 | Jun 17, 2025 | |
| RNA Avidity Biosciences | Initiates: Outperform | $55 | $72.20 | -23.82% | 1 | Jun 17, 2025 | |
| MLTX MoonLake Immunotherapeutics | Upgrades: Outperform | $61 | $13.87 | +339.80% | 3 | May 19, 2025 | |
| ANAB AnaptysBio | Initiates: Outperform | n/a | $50.01 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $48.71 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $32.09 | -37.68% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $43.21 | -56.03% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $26.88 | - | 2 | Jan 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $100.44 | - | 1 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $26.83 | - | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $65 | $83.33 | -22.00% | 2 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $602.82 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $32.28 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $35.84 | - | 3 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $80.65 | - | 1 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $56.71 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $22.50 | -24.44% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $462.99 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $177.42 | -76.33% | 1 | Feb 15, 2024 |
argenx SE
Nov 24, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $849.95
Upside: -
Intellia Therapeutics
Nov 12, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $9.59
Upside: -
Apellis Pharmaceuticals
Nov 6, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $25.16
Upside: -
Alnylam Pharmaceuticals
Aug 4, 2025
Upgrades: Peer Perform
Price Target: n/a
Current: $400.69
Upside: -
Vera Therapeutics
Aug 4, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $55.67
Upside: -
BridgeBio Pharma
Jun 17, 2025
Initiates: Outperform
Price Target: $49
Current: $76.53
Upside: -35.97%
Sarepta Therapeutics
Jun 17, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $22.32
Upside: -
Avidity Biosciences
Jun 17, 2025
Initiates: Outperform
Price Target: $55
Current: $72.20
Upside: -23.82%
MoonLake Immunotherapeutics
May 19, 2025
Upgrades: Outperform
Price Target: $61
Current: $13.87
Upside: +339.80%
AnaptysBio
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $50.01
Upside: -
Feb 4, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $48.71
Upside: -
Feb 4, 2025
Initiates: Outperform
Price Target: $20
Current: $32.09
Upside: -37.68%
Feb 4, 2025
Initiates: Outperform
Price Target: $19
Current: $43.21
Upside: -56.03%
Jan 3, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $26.88
Upside: -
Oct 1, 2024
Initiates: Outperform
Price Target: n/a
Current: $100.44
Upside: -
Sep 27, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $26.83
Upside: -
Aug 26, 2024
Upgrades: Outperform
Price Target: $65
Current: $83.33
Upside: -22.00%
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $602.82
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $32.28
Upside: -
May 14, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $35.84
Upside: -
Apr 10, 2024
Upgrades: Outperform
Price Target: n/a
Current: $80.65
Upside: -
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $56.71
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $17
Current: $22.50
Upside: -24.44%
Feb 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $462.99
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $42
Current: $177.42
Upside: -76.33%